Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant adverse » significant advantage (Expand Search)
adverse decrease » rivers decreased (Expand Search)
Showing 301 - 320 results of 1,160 for search '(( significant decrease decrease ) OR ( significant adverse decrease ))~', query time: 0.22s Refine Results
  1. 301
    Gene ontology enrichment analysis.

    Gene ontology enrichment analysis. by Zeynab Hosseinpoor (19762319)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 302
    KEGG pathway enrichment and PPI network of <i>MIR-96</i> associated genes.

    KEGG pathway enrichment and PPI network of <i>MIR-96</i> associated genes. by Zeynab Hosseinpoor (19762319)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 303
    Effects of <i>MIR-96</i> on cell viability.

    Effects of <i>MIR-96</i> on cell viability. by Zeynab Hosseinpoor (19762319)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 304
    Participant flow (CONSORT diagram).

    Participant flow (CONSORT diagram). by David J. Diemert (8135568)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 305
    Geometric mean anti-<i>Na</i>-GST-1 IgG levels over time by vaccine group, as measured by ELISA (Arbitrary Units).

    Geometric mean anti-<i>Na</i>-GST-1 IgG levels over time by vaccine group, as measured by ELISA (Arbitrary Units). by David J. Diemert (8135568)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 306
    Demographic and baseline characteristics of study participants by vaccine group.

    Demographic and baseline characteristics of study participants by vaccine group. by David J. Diemert (8135568)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 307
    Geometric mean anti-<i>Na</i>-GST-1 IgG subclass levels over time.

    Geometric mean anti-<i>Na</i>-GST-1 IgG subclass levels over time. by David J. Diemert (8135568)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 308
    Anti-<i>Na</i>-GST-1 IgG antibody levels and seroresponse rates by vaccine group and study day.

    Anti-<i>Na</i>-GST-1 IgG antibody levels and seroresponse rates by vaccine group and study day. by David J. Diemert (8135568)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 309
    Number and percentage of participants experiencing solicited injection site and systemic reactions by maximum severity and vaccine group.

    Number and percentage of participants experiencing solicited injection site and systemic reactions by maximum severity and vaccine group. by David J. Diemert (8135568)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 310
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 311
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 312
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  13. 313
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  14. 314
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  15. 315
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  16. 316
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  17. 317
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  18. 318
    Changes in the neutrophil count.

    Changes in the neutrophil count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
    Save to List
    Saved in:
  19. 319
    Changes in the platelet count.

    Changes in the platelet count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
    Save to List
    Saved in:
  20. 320
    Changes in the white blood cell count.

    Changes in the white blood cell count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
    Save to List
    Saved in:

Search Tools: